Abstracts tagged "Biologicals"

Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 0517 • ACR Convergence 2024
Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung², Chang-Hee Suh³ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, South Korea, ²Ajou University of medical school, Suwon, South Korea, ³Ajou University Hospital, Suwon, South Korea
Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
Abstract Number: 0591 • ACR Convergence 2024
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Jessica A Walsh¹, Joseph F. Merola², Christopher T Ritchlin³, Yoshiya Tanaka⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and William Tillett¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²UT Southwestern Medical Center, Dallas, TX, ³Allergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁶National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic disease, and patients (pts) can experience loss of response with sustained therapy; therefore, assessing long-term maintenance of response in pts…
Abstract Number: 0849 • ACR Convergence 2024
Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Iñigo Hernández-Rodríguez⁴, Susana Romero Yuste⁵, Eugenio De Miguel⁶, Eva Galindez-Agirregoikoa⁷, ivan Ferraz-Amaro⁸, Julio Sánchez-Martín⁹, Patricia Moya Albarado¹⁰, Cristina Campos Fernández¹¹, Fernando Lopez-Gutierrez¹², Santos Castañeda¹³ and Ricardo Blanco-Alonso¹⁴, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁵Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital de San Pau, Barcelona, Spain, ¹¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
Abstract Number: 1132 • ACR Convergence 2024
Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Dylan Richards¹, Marion Vetter¹, Matthew Germinaro¹, Bram Verstockt², Raja Atreya³, Julián Panés⁴, Bruce E. Sands⁵, Brian G. Feagan⁶, Bradford McRae⁷, Daniel Cua¹, Patrick Branigan¹ and Tom C. Freeman¹, ¹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ²Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium, ³Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY, ⁶Alimentiv Inc, London, ON, Canada, London, ON, Canada, ⁷Janssen Research & Development, Cambridge, MA, USA, Cambridge, MA
Background/Purpose: Combination induction therapy with guselkumab (GUS), an interleukin (IL)-23p19 subunit antagonist, and golimumab (GOL), a tumor necrosis factor (TNFα) antagonist, induced higher rates of…
Abstract Number: 1457 • ACR Convergence 2024
Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Gonul Hazal Koc¹, Marc R. Kok², Fazira R. Kasiem³, Jolanda Luime³, Ilja Tchetverikov⁴, Kim Wilhelm - de Jong³, Lindy A. Korswagen⁵, Jessica Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Paul Baudoin⁸, Petra Kok⁹, Reinhard Bos¹⁰, radboud J.e.m. Dolhain¹¹ and Marijn Vis³, ¹Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, North Brabant, Netherlands, ⁷Haga Hospital, Den Haag, Netherlands, ⁸Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Reinier de Graaf Gasthuis, Delft, Netherlands, ¹⁰Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: The Strategy Treatments aiming at Minimal Disease Activity in PsA (STAMP) is a one-year randomized controlled trial designed to investigate the efficacy of two…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
Abstract Number: 2011 • ACR Convergence 2024
The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase
Sanjay Chabra¹, Afroz Mohammad², Katie Obermeyer², Yang Song², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹Texas Arthritis Center, El Paso, TX, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Immunogenicity of pegloticase, a PEGylated uricase, can limit a sustained urate-lowering response and increase risk for infusion reactions (IRs).1 The MIRROR RCT trial demonstrated…
Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 2482 • ACR Convergence 2024
Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Gerhard Wolff¹, Michael E Wechsler², Jared Silver³, Robert Price⁴, Rejina Verghis⁵, Peter Weller⁶, Peter Merkel⁷, Thomas Corbridge⁸ and Paneez Khoury⁹, ¹Clinical Development-Respiratory, GSK, Collegeville, ²Department of Medicine, National Jewish Health, Denver, CO, ³US Medical Affairs-Respiratory, GSK, Durham, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ⁸US Value Evidence and Outcomes, GSK, Durham, NC, ⁹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…
Abstract Number: 0399 • ACR Convergence 2024
Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort
Rachel Dickey¹, Doel Dhar², Srushti Gangireddy³, Henry H. Ong³, Wei-Qi Wei³ and Anna Patrick³, ¹Lipscomb University College of Pharmacy, Athens, TN, ²Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe disease with symptoms of fevers, rash, and arthritis. High levels of the inflammatory cytokines interlukin-1 (IL-1)…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Siddhartha Sood¹, Alexander Rimke², Brian Rankin³, Abrahim Abduelmula⁴, jorge Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit⁵, Fernejoy Leung⁶, Alim Devani⁶, Ronald Vender⁷, Jensen Yeung⁴ and Vimal Prajapati³, ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Dermatology Research Institute, Calgary, AB, Canada, ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada, ⁵Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, ⁶Skin Health & Wellness Centre, Calgary, AB, Canada, ⁷Division of Dermatology, Department of Medicine, McMaster University, Hamilton, Canada
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].